Otsuka Acquires Rights to DacogenA from Eisai

Otsuka Pharmaceutical Co., Ltd.has announced an agreement with Eisai Inc., a U.S. subsidiary of Eisai Co., Ltd. to acquire rights to the hematological cancer treatment Dacogen A and to an enzyme inhibitor, E7727.

http://ift.tt/1fG49yz